206 related articles for article (PubMed ID: 15331695)
1. Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens.
Kang SM; Guo L; Yao Q; Skountzou I; Compans RW
J Virol; 2004 Sep; 78(18):9624-32. PubMed ID: 15331695
[TBL] [Abstract][Full Text] [Related]
2. Th cell-independent immune responses to chimeric hemagglutinin/simian human immunodeficiency virus-like particles vaccine.
Yao Q; Zhang R; Guo L; Li M; Chen C
J Immunol; 2004 Aug; 173(3):1951-8. PubMed ID: 15265929
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of mucosal immune responses by chimeric influenza HA/SHIV virus-like particles.
Guo L; Lu X; Kang SM; Chen C; Compans RW; Yao Q
Virology; 2003 Sep; 313(2):502-13. PubMed ID: 12954217
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of mucosal immune responses by chimeric influenza HA/SHIV virus-like particles.
Yao Q
Res Initiat Treat Action; 2003; 8(2):20-1. PubMed ID: 12845773
[TBL] [Abstract][Full Text] [Related]
5. CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides.
Jiang JQ; Patrick A; Moss RB; Rosenthal KL
J Virol; 2005 Jan; 79(1):393-400. PubMed ID: 15596832
[TBL] [Abstract][Full Text] [Related]
6. Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques.
Miyake A; Akagi T; Enose Y; Ueno M; Kawamura M; Horiuchi R; Hiraishi K; Adachi M; Serizawa T; Narayan O; Akashi M; Baba M; Hayami M
J Med Virol; 2004 Jul; 73(3):368-77. PubMed ID: 15170630
[TBL] [Abstract][Full Text] [Related]
7. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus.
Kang SM; Compans RW
J Virol; 2003 Mar; 77(6):3615-23. PubMed ID: 12610137
[TBL] [Abstract][Full Text] [Related]
9. Intranasal immunization with SIV virus-like particles (VLPs) elicits systemic and mucosal immunity.
Yao Q; Vuong V; Li M; Compans RW
Vaccine; 2002 Jun; 20(19-20):2537-45. PubMed ID: 12057610
[TBL] [Abstract][Full Text] [Related]
10. Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge.
Dumais N; Patrick A; Moss RB; Davis HL; Rosenthal KL
J Infect Dis; 2002 Oct; 186(8):1098-105. PubMed ID: 12355360
[TBL] [Abstract][Full Text] [Related]
11. H9N2 influenza whole inactivated virus combined with polyethyleneimine strongly enhances mucosal and systemic immunity after intranasal immunization in mice.
Qin T; Yin Y; Huang L; Yu Q; Yang Q
Clin Vaccine Immunol; 2015 Apr; 22(4):421-9. PubMed ID: 25673304
[TBL] [Abstract][Full Text] [Related]
12. Modified pulmonary surfactant is a potent adjuvant that stimulates the mucosal IgA production in response to the influenza virus antigen.
Mizuno D; Ide-Kurihara M; Ichinomiya T; Kubo I; Kido H
J Immunol; 2006 Jan; 176(2):1122-30. PubMed ID: 16394001
[TBL] [Abstract][Full Text] [Related]
13. AIDS vaccine: Intranasal immunization using inactivated HIV-1-capturing core-corona type polymeric nanospheres.
Akagi T; Ueno M; Hiraishi K; Baba M; Akashi M
J Control Release; 2005 Dec; 109(1-3):49-61. PubMed ID: 16256237
[TBL] [Abstract][Full Text] [Related]
14. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
Hong SH; Byun YH; Nguyen CT; Kim SY; Seong BL; Park S; Woo GJ; Yoon Y; Koh JT; Fujihashi K; Rhee JH; Lee SE
Vaccine; 2012 Jan; 30(2):466-74. PubMed ID: 22051136
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteins.
Quan FS; Sailaja G; Skountzou I; Huang C; Vzorov A; Compans RW; Kang SM
Vaccine; 2007 May; 25(19):3841-50. PubMed ID: 17320250
[TBL] [Abstract][Full Text] [Related]
16. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A).
Staats HF; Nichols WG; Palker TJ
J Immunol; 1996 Jul; 157(1):462-72. PubMed ID: 8683152
[TBL] [Abstract][Full Text] [Related]
17. An α-GalCer analogue with branched acyl chain enhances protective immune responses in a nasal influenza vaccine.
Lee YS; Lee KA; Lee JY; Kang MH; Song YC; Baek DJ; Kim S; Kang CY
Vaccine; 2011 Jan; 29(3):417-25. PubMed ID: 21087689
[TBL] [Abstract][Full Text] [Related]
18. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).
Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O
Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906
[TBL] [Abstract][Full Text] [Related]
19. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
20. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice.
Takada A; Matsushita S; Ninomiya A; Kawaoka Y; Kida H
Vaccine; 2003 Jul; 21(23):3212-8. PubMed ID: 12804850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
